UroGen Pharma
URGN
84 hedge funds and large institutions have $527M invested in UroGen Pharma in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 14 closing their positions.
161% more call options, than puts
Call options by funds: $1.44M | Put options by funds: $553K
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
42% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 19
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
14% more funds holding
Funds holding: 74 → 84 (+10)
6% more capital invested
Capital invested by funds: $497M → $527M (+$30M)
4.88% more ownership
Funds ownership: 65.73% → 70.62% (+4.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$33.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$10.6M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$3.8M |
| 4 |
DG
Delek Group
Herzliya,
Israel
|
+$3.51M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$12M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.6M |
| 3 |
Man Group
London,
United Kingdom
|
-$5.99M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.5M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.29M |
URGN Hedge Fund Activity: Q2 2019 in Review
84 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2019, worth a combined $527M — up 6% from $497M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new URGN positions and 14 closed out — a net gain of 11 holders — while 27 added to existing stakes and 19 trimmed.
The largest buyer was BlackRock, adding an estimated $33.8M. The largest seller was Consonance Capital Management, cutting an estimated $12M.
- 84 institutional investors held UroGen Pharma (URGN) as of Q2 2019, up from 74 in Q1 2019.
- Funds reported $527M of UroGen Pharma stock for Q2 2019, up 6% quarter-over-quarter.
- 25 funds opened new UroGen Pharma positions in Q2 2019 and 14 closed out, a net change of +11 holders.
- The largest UroGen Pharma buyer in Q2 2019 was BlackRock, an estimated $33.8M added.
- The largest UroGen Pharma seller in Q2 2019 was Consonance Capital Management, an estimated $12M sold.
Based on aggregated 13F filings for Q2 2019.